Chemokines and Chemokine Receptors in the Development of Lupus Nephritis

Liao, Xiaofeng; Pirapakaran, Tharshikha; Luo, Xin

doi:10.1155/2016/6012715

Cited by 57 publications

(55 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The axes of IFN-g:CXCL10:CXCR3 and CCL4:CCR5 are thus likely to recruit gluten-specific CD4 + T cells into the celiac lesion. Although disease-specific cells have not been demonstrated in most other autoimmune diseases, increased numbers of CCR5 + , CXCR3 + , CD4 + T cells or increased levels of their receptor ligands have been reported in patient cohorts with different autoimmune conditions, including T1D [57], MS [58,59], RA [60,61], SLE [62], Ssc [63], psoriasis [64,65], and in several murine autoimmune models [66,67].…”

Section: Blocking Infiltration To the Inflammatory Tissuementioning

confidence: 99%

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Christophersen

Risnes

Dahal‐Koirala

et al. 2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

Few therapeutic and diagnostic tools specifically aim at T cells in autoimmune disorders, but are T cells a narrow target in these diseases? Lessons may be learned from celiac disease (CeD), one of the few autoimmune disorders where the T cell driving antigens are known, i.e. dietary gluten proteins. T cell clonotypes specific to gluten are expanded, persist for decades and express a distinct phenotype in CeD patients. Cells with this phenotype are increased also in other autoimmune conditions. Accordingly, disease-specific CD4 + T cells form an immunological scar in CeD and probably other autoimmune disorders. We discuss approaches how such T cells may be targeted for better treatment and diagnosis via their antigen specificity or via their expression of characteristic phenotypic markers.

show abstract

Section: Blocking Infiltration To the Inflammatory Tissuementioning

confidence: 99%

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Christophersen

Risnes

Dahal‐Koirala

et al. 2019

Trends in Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…It will be also interesting to examine the chemokine expression levels in nephritic kidneys. The chemokines CCL2, CCL3, CCL5, CXCL10, CXCL12, CXCL13, and CX3CL1 are expressed in the nephritic kidney of lupus-prone mice and SLE patients and increase inflammatory cell infiltration into the kidney [ 29 ]. Further clinical studies will be also required to address whether PD or MMF affects MSC functions in patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL.Fas^lpr Mice

Lee

Kim

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

The combination of immunosuppressants and mesenchymal stem cells (MSCs) is a promising therapeutic strategy for systemic lupus erythematosus, since this approach reduces doses of immunosuppressants while maintaining the same therapeutic outcome. However, it is unavoidable for MSCs to be exposed to immunosuppressants. Here, we examined the combination effect of prednisone (PD) or mycophenolate mofetil (MMF) and MSCs. We showed that PD or MMF in combination with MSCs showed better therapeutic effect than single therapy in lupus-prone MRL.Faslpr mice, as assessed by using the following readouts: prolongation of survival, decrease in anti-dsDNA and total IgG levels in serum, decrease in cytokine gene expression in spleen cells, and decrease in inflammatory cell infiltration into the kidney. In vitro, immunosuppressants and MSCs inhibited T cell proliferation in a synergistic manner. However, immunosuppressants did not affect MSC viability and functions such as TGF-β1 and PGE2 production, migration, and immunosuppressive capacity. In summary, our study demonstrates that a combination of immunosuppressants and MSCs is a good strategy to reduce the side effects of PD and MMF without the loss of therapeutic outcome.

show abstract

“…Chemokines are a group of cytokines, whose main action is to recruit leukocyte subsets under homeostatic and pathological conditions. These chemokines play important roles during the inflammation; for example, MIP-17 α (CXCL3) and RANTES (CXCL5) can bind to receptor CXCR5 and can circulate and migrate immune cells such as neutrophils, monocytes, and effector T cells into inflamed tissues [ 37 ]. Over the past decade, the concept of targeting cytokines to treat autoimmune diseases has evolved at a rapid pace, such as some medicines approved by the drug administration to target IL-1 β , IL-5, IL-6, IL-2, TNF- α , and IFN- γ [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Stabilizedβ-Catenin Ameliorates ALPS-Like Symptoms of B6/lprMice

Huang

Zhao

et al. 2017

Journal of Immunology Research

View full text Add to dashboard Cite

Autoimmune lymphoproliferative syndrome (ALPS) is an incurable disease mainly caused by the defect of Fas-mediated apoptosis and characterized by nonmalignant autoimmune lymphoproliferation. Stabilized β-catenin could not only potentiate Fas-mediated T cell apoptosis via upregulating the expression of Fas on activated T cells, but also potentiate T cell apoptosis via intrinsic apoptotic pathway. In the present study, we introduced β-cat Tg into lpr/lpr mice and aimed to explore the potential role of stabilized β-catenin (β-cat Tg ) in the development of ALPS-like phenotypes of lpr/lpr mice. We found that the total splenocyte cells and some compositions were slightly downregulated in β-cat Tg lpr/lpr mice, especially the CD4 and CD8 T EM cells were significantly reduced. Meanwhile, stabilized β-catenin obviously decreased the numbers of spleen TCRβ + CD4 − CD8 − T (DNT) cells, and the levels of some serum proinflammatory factors also were lowered in β-cat Tg lpr/lpr mice. Beyond that, stabilized β-catenin slightly lowered the levels of the serum autoantibodies and the scores of kidney histopathology of β-cat Tg lpr/lpr mice compared with lpr/lpr mice. Our study suggested that stabilized β-catenin ameliorated some ALPS-like symptoms of lpr/lpr mice by potentiating Fas-independent signal-mediated T cell apoptosis, which might uncover a potential novel therapeutic direction for ALPS.

show abstract

Chemokines and Chemokine Receptors in the Development of Lupus Nephritis

Cited by 57 publications

References 143 publications

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL.Fas^lpr Mice

Stabilizedβ-Catenin Ameliorates ALPS-Like Symptoms of B6/lprMice

Contact Info

Product

Resources

About

Chemokines and Chemokine Receptors in the Development of Lupus Nephritis

Cited by 57 publications

References 143 publications

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Therapeutic and Diagnostic Implications of T Cell Scarring in Celiac Disease and Beyond

Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL.Faslpr Mice

Stabilizedβ-Catenin Ameliorates ALPS-Like Symptoms of B6/lprMice

Contact Info

Product

Resources

About

Effect of a Combination of Prednisone or Mycophenolate Mofetil and Mesenchymal Stem Cells on Lupus Symptoms in MRL.Fas^lpr Mice